Sumitomo Buys Into Cytel In USA

5 December 1994

Japanese pharmaceuticals company Sumitomo has acquired an 8% stake in Cytel Corporation in the USA, the latter being a bioventure business company with which it has collaborative deals. The stake Sumitomo has taken is worth $5 million.

The two companies entered into a collaborative agreement in 1991 focussing on research into white blood cell diseases and cancer. The collaborative research has resulted in a new candidate drug, cylexin, reports Pharma Japan. It is Sumitomo's second new candidate drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight